Study population
PERITONEAL CARCINOMATOSIS, METASTASIS, ADENOCARCINOMA
Adult patients (18–75 years old) with gastric and GEJ adenocarcinoma with positive peritoneal cytology or peritoneal carcinomatosis detected by laparoscopy, laparotomy, or imaging and without evidence of distant organ metastasis and no evidence of progression after 3–4 months of first-line systemic therapy are eligible for this study (Fig. Study schemaThe key inclusion and exclusion criteria are listed in Table STOPGAP trial key inclusion and exclusion criteriaRestaging imaging with CT chest and CT abdomen and pelvis and /or diffusion weighted MRI of abdomen and pelvis with contrast will be obtained after completion of systemic therapy. In the absence of distant organ metastatic progression, patients will be deemed eligible to participation in the trial.